Aroa Biosurgery (ARX) Hisse Özeti
Aroa Biosurgery Limited, Amerika Birleşik Devletleri'nde ve uluslararası alanda ekstraselüler matris (ECM) teknolojisini kullanarak yara ve yumuşak doku onarımı için tıbbi cihazlar geliştirmekte, üretmekte ve satmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 3/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden ARX için herhangi bir risk tespit edilmedi.
ARX Community Fair Values
Create NarrativeSee what 49 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aroa Biosurgery Limited Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | AU$0.65 |
| 52 Haftanın En Yüksek Seviyesi | AU$0.80 |
| 52 Haftanın En Düşük Seviyesi | AU$0.46 |
| Beta | 0.84 |
| 1 Aylık Değişim | 4.03% |
| 3 Aylık Değişim | 7.50% |
| 1 Yıllık Değişim | 22.86% |
| 3 Yıllık Değişim | -27.12% |
| 5 Yıllık Değişim | -39.72% |
| Halka arzdan bu yana değişim | -52.22% |
Son Haberler & Güncellemeler
ARX: Positive Trial Results Will Underpin Future Earnings Power
Analysts have nudged their price target for Aroa Biosurgery higher to A$1.09 from A$1.07, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, projecting total revenue of about NZ$104 million on an actual basis, citing stronger than expected sales in the Myriad portfolio and favourable foreign exchange movements.ARX: Positive Wound Trial Results Will Support Stronger Future Profitability
Analysts have lifted their price target for Aroa Biosurgery from A$0.83 to A$1.07, citing updated assumptions that include a higher discount rate, a slightly adjusted revenue growth outlook, a stronger forecast profit margin, and a lower future P/E multiple. What's in the News Aroa Biosurgery reported completion of its randomised controlled trial of Symphony, a skin substitute designed for hard to heal wounds such as diabetic foot ulcers and venous leg ulcers, with a preliminary read out indicating the primary endpoint was achieved (Key Developments).
Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?Recent updates
ARX: Positive Trial Results Will Underpin Future Earnings Power
Analysts have nudged their price target for Aroa Biosurgery higher to A$1.09 from A$1.07, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, projecting total revenue of about NZ$104 million on an actual basis, citing stronger than expected sales in the Myriad portfolio and favourable foreign exchange movements.ARX: Positive Wound Trial Results Will Support Stronger Future Profitability
Analysts have lifted their price target for Aroa Biosurgery from A$0.83 to A$1.07, citing updated assumptions that include a higher discount rate, a slightly adjusted revenue growth outlook, a stronger forecast profit margin, and a lower future P/E multiple. What's in the News Aroa Biosurgery reported completion of its randomised controlled trial of Symphony, a skin substitute designed for hard to heal wounds such as diabetic foot ulcers and venous leg ulcers, with a preliminary read out indicating the primary endpoint was achieved (Key Developments).Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?
Outpatient Expansion And Surgical Partnerships Will Transform Long Term Prospects For This Biologics Supplier
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, trauma, burns and reconstructive surgery. What are the underlying business or industry changes driving this perspective?Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Aroa Biosurgery Limited ( ASX:ARX ) last week reported its latest half-yearly results, which makes it a good time for...
Lebanon, Vietnam, And Saudi Arabia Approvals Will Secure Market Presence
Expansion into international markets and positive clinical outcomes suggest potential revenue growth as new regions adopt Aroa's cost-effective products.Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Unfortunately for some shareholders, the Aroa Biosurgery Limited ( ASX:ARX ) share price has dived 26% in the last...Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%
Aroa Biosurgery Limited ( ASX:ARX ) shares have continued their recent momentum with a 26% gain in the last month...The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders that were waiting for something to happen have been dealt a blow with...Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 4.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Shareholders in Aroa Biosurgery Limited ( ASX:ARX ) may be thrilled to learn that the analysts have just delivered a...Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Does the October share price for Aroa Biosurgery Limited ( ASX:ARX ) reflect what it's really worth? Today, we will...We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results
Investors in Aroa Biosurgery Limited ( ASX:ARX ) had a good week, as its shares rose 6.2% to close at AU$1.20 following...An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Aroa Biosurgery...Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?
A look at the shareholders of Aroa Biosurgery Limited ( ASX:ARX ) can tell us which group is most powerful...Hissedar Getirileri
| ARX | AU Biotechs | AU Pazar | |
|---|---|---|---|
| 7D | -4.4% | 6.0% | -1.6% |
| 1Y | 22.9% | -55.9% | -0.4% |
Getiri vs. Endüstri: ARX geçen yıl % -55.9 oranında getiri sağlayan Australian Biotechs sektörünü aştı.
Getiri vs Piyasa: ARX geçen yıl % -0.4 oranında getiri sağlayan Australian Piyasasını aştı.
Fiyat Oynaklığı
| ARX volatility | |
|---|---|
| ARX Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 10.1% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 4.0% |
İstikrarlı Hisse Senedi Fiyatı: ARX son 3 ayda Australian piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: ARX 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2007 | n/a | Brian Ward | aroa.com |
Aroa Biosurgery Limited, Amerika Birleşik Devletleri'nde ve uluslararası alanda ekstraselüler matris (ECM) teknolojisini kullanarak yara ve yumuşak doku onarımı için tıbbi cihazlar geliştirmekte, üretmekte ve satmaktadır. Ürünleri arasında akut ve kronik yaraların tedavisi için Endoform Natural ve Endoform Antimicrobial Restorative Bioscaffold; yumuşak doku onarımı, takviyesi ve karmaşık yaralar için tasarlanmış bir ECM olan Myriad Matrix; yumuşak doku onarımı ve karmaşık yaralar için Myriad Matrix'in morselleştirilmiş (toz haline getirilmiş) bir formatı olan Myriad Morcells bulunmaktadır; İyileşmeyi başlatmaya ve sürdürmeye yardımcı olmak için biyolojik olarak önemli ECM proteinlerinden oluşan bir bolus sağlayan Myriad Morcells Fine; ve karmaşık yaralarda fonksiyonel dokunun yenilenmesi için endike bir kombinasyon hücresel ve doku ürünü olan Symphony. Şirket ayrıca Kuzey Amerika ve Avrupa'da abdominal duvar rekonstrüksiyonu, fıtık onarımı ve meme rekonstrüksiyonu için ürünler geliştirmektedir.
Aroa Biosurgery Limited Temel Bilgiler Özeti
| ARX temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | AU$223.11m |
| Kazançlar(TTM) | AU$3.88m |
| Gelir(TTM) | AU$86.12m |
ARX aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ARX gelir tablosu (TTM) | |
|---|---|
| Gelir | NZ$103.85m |
| Gelir Maliyeti | NZ$15.03m |
| Brüt Kâr | NZ$88.83m |
| Diğer Giderler | NZ$84.15m |
| Kazançlar | NZ$4.68m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 0.014 |
| Brüt Marj | 85.53% |
| Net Kâr Marjı | 4.50% |
| Borç/Özkaynak Oranı | 0% |
ARX uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/10 22:36 |
| Gün Sonu Hisse Fiyatı | 2026/06/10 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Aroa Biosurgery Limited 4 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| John Hester | Bell Potter |
| Shane Storey | Canaccord Genuity |
| Scott Power | Morgans Financial Limited |